Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03150914 · ClinicalTrials.gov registry record · Phase 3
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
A Phase 3 study of Lymphangioleiomyomatosis and LAM, sponsored by University of Cincinnati.
- Active
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 8
- Study locations
NCT03150914: Active Phase 3 study of Lymphangioleiomyomatosis and LAM, sponsored by University of Cincinnati.
NCT03150914 is a Phase 3 study of Lymphangioleiomyomatosis and LAM that is active but no longer recruiting, run by University of Cincinnati. The registered enrollment target is 60 participants, below the 824-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03150914, a Phase 3 study of Lymphangioleiomyomatosis and LAM, is active but no longer recruiting, sponsored by University of Cincinnati.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.
Primary Outcome
Rate of lung function decline
Conditions Studied
Interventions
- DRUG Sirolimus
Study Locations (8)
California
- Stanford University - Palo Alto
Colorado
- National Jewish Hospital - Denver
Georgia
- Emory University - Atlanta
Illinois
- Loyola University - Chicago
Massachusetts
- Brigham and Woman's Hospital - Boston
Ohio
- University of Cincinnati - Cincinnati
Pennsylvania
- University of Pennsylvania - Philadelphia
Washington
- Swedish Health - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 3 |
What the registry record for NCT03150914 still lists
NCT03150914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 824-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Lymphangioleiomyomatosis appearing as the primary indexed condition, and to 1 intervention - of which Sirolimus is the first listed.
NCT03150914 lists 8 locations in 8 states (California, Colorado, Georgia).
Frequently Asked Questions
What is clinical trial NCT03150914 about?
NCT03150914 is a clinical study titled "Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial". This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.
What is the current status of trial NCT03150914?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2018-01-01. Estimated completion is 2025-06-30.
What conditions does trial NCT03150914 study?
This clinical trial studies the following conditions: Lymphangioleiomyomatosis, LAM.
What interventions are being tested in trial NCT03150914?
The interventions under investigation include: Sirolimus (DRUG).
Who is sponsoring clinical trial NCT03150914?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03150914 being conducted?
This trial has 8 study locations across California, Colorado, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphangioleiomyomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03150914's enrollment target sits among peer trials
60 7th of 10 higher than 4 of 10 other Lymphangioleiomyomatosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphangioleiomyomatosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
RECRUITING · Phase 1
-
Safety and Durability of Sirolimus for Treatment of LAM
RECRUITING
-
TSC Biosample Repository and Natural History Database
RECRUITING
-
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
RECRUITING
-
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
RECRUITING · Phase 1
-
Study of the Disease Process of Lymphangioleiomyomatosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI